The EMA has published new guidance in response to #MedicinesShortages . Commenting in the The Pharmaceutical Journal, our CEO Mark Samuels said:

“To restore resilience, government policy must recognise the vital role the off-patent medicines sector has.” Read more: bit.ly/49SL3Xx

Over 2 billion people lack access to healthcare globally. International Health Partners play a vital role in getting medicines to disaster-hit and vulnerable communities.

Watch their video and consider donating to the #BridgingtheGap Fund while donations are being matched: justgiving.com/campaign/ihpbr…

What’s at stake for the #NHS from the policies of an incoming Government?

Well, £18bn in potential NHS savings from medicines due to come off patent over the next five years - that could be realised with a proactive, supportive policy environment.

bit.ly/3PCKGJf

A new report from Nuffield Trust highlights the 'new normal' of medicines shortages, offering key policy recommendations, including mutual recognition of batch testing between the EU and UK - something we have also long made a case for at the BGMA: nuffieldtrust.org.uk/research/the-f…

#BiosimilarMedicines policies are key contributors to maximising value in health, positively impacting patient access and healthcare systems globally.

#BIOS24 starts today with lots of information on the value biosimilar medicines bring to both patients and healthcare systems.

We are pleased to support the Government's efforts to secure the UK's supplies of critical goods, with the launch of the #CriticalImportsCouncil - and welcome our inclusion as the sector that supplies 4 out of 5 prescription drugs the NHS uses: gov.uk/government/new…

Over 20 years, donations of unused generic medicines have helped millions of people globally, in regions like Ukraine, Malawi and Haiti.

Find out more about supporting International Health Partners’s #BridgingTheGap campaign, while donations are being matched: justgiving.com/campaign/ihpbr…

Future trade deals must protect the careful balance in the UK intellectual property framework between rewarding innovation and enabling fair competition that keeps medicines affordable for NHS patients.

Further detail in our Manifesto: bit.ly/3PCKGJf

#Trade

Our April generic medicines supply issues dashboard is now live on our website, showing c. 25% generics in short supply for over 12 months and c. 45% for over 6 months.

The level of products being discontinued was much higher than usual. Next month will tell us if this is a…

Britain must act or lose the global medicines competition.

Read BGMA CEO Mark Samuels thought piece in the Financial Times today to learn whats at stake - and what politicians can do to protect critical medicines access and save the NHS £18bn:
ft.com/content/b7fc88…

Yesterday International Health Partners launched its #BridgingtheGap Fund – a new big push to ensure people in disaster-hit and vulnerable communities can access vital medicines.

With more funds, IHP will be able to more rapidly respond to crises and support affected communities long term, despite…

The #BIOS24  Conference brings together healthcare leaders and experts to discuss how #biosimilarmedicines policies contribute to maximising value in health.

Explore the latest developments and trends in biosimilar medicines in Amsterdam on 18-19 April: medicinesforeurope.com/events/bios24/

In the face of continual #medicineshortages , fresh policy thinking is needed to restore UK medicines supply chain resilience.

A new fast-track license for products in shortage, for example, could help alleviate pressure.

More detail in the Manifesto: bit.ly/3PCKGJf

Our new manifesto outlines how the Government can support the UK off-patent, essential medicines sector to strengthen domestic growth, supply resilience & export competitiveness through funding & policy representation.

Read Chapter 2 on domestic growth: bit.ly/3PCKGJf

New off-patent drugs could save the #NHS a whopping £18 billion over the next five years.

This will only be fully realised with a more supportive policy environment and a national strategy for #biosimilars .

Detailed recommendations in our Manifesto: bit.ly/3PCKGJf

The UK is becoming a medicines supply “backwater” claims BGMA.
independentpharmacist.co.uk/news/1220524-u…

UK faces risk of becoming a ‘backwater’ supply market for medicines, BGMA manifesto warns
Read more- pharmacy.biz/news/uk-faces-…
#BGMAmanifesto
#drugshortage
#offpatentmedicines
#genericmedicines

We've just launched our new #manifesto for building a resilient UK medicines industry.

Download it today to learn how off-patent policy changes could build medicines supply resilience & global competitiveness, save the NHS money & widen patient access: bit.ly/3PCKGJf

ICYMI: 'While EU countries are planning to work together to stockpile reliable supplies of 200 commonly used medications, here in the UK, policy makers are failing to address the ongoing issues of #medicineshortages '

Mark Samuels BGMA
mims.co.uk/analysis-why-g…

Britain is failing to stay competitive on generics and biosimilars in the fight for supply with the rest of Europe and the US.

The UK Government needs to invest in the sector. Read more in Bloomberg:
bloomberg.com/news/articles/…

#UKMedicines #healthpolicy #drugshortages